FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3189683257> ?p ?o ?g. }

• W3189683257 abstract "You have accessJournal of UrologyBenign Prostatic Hyperplasia: Epidemiology & Evaluation (MP28)1 Sep 2021MP28-17 PROSTATE ZONAL VOLUMES MAY PREDICT 5ARI THERAPY RESPONSIVENESS Xingbo Long, Christina Sharkey, Zongwei Wang, Boris Gershman, Leo Tsai, and Aria F. Olumi Xingbo LongXingbo Long More articles by this author , Christina SharkeyChristina Sharkey More articles by this author , Zongwei WangZongwei Wang More articles by this author , Boris GershmanBoris Gershman More articles by this author , Leo TsaiLeo Tsai More articles by this author , and Aria F. OlumiAria F. Olumi More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002025.17AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Benign prostatic hyperplasia (BPH) is highly prevalent in elderly men and is a major cause of lower urinary tract symptoms (LUTS). The zonal growth rate of the prostate and response to 5-alpha reductase inhibitor (5ARI) varies among BPH patients. Currently, one of the main medical therapies for BPH is 5-alpha reductase inhibitor (5ARI). While the variable growth rate of the total prostate gland is recognized, the variable growth rate of different prostate zones and their response to 5ARI treatment among adult male remains largely unclear. We evaluated the variable growth rate of different prostate zones and their response to 5ARI treatment. METHODS: Prostate MRI data and clinical information were obtained retrospectively on 160 patients who had a history of BPH or low-grade prostate cancer and underwent at least three prostate MRIs between 2003 and 2018. Prostate volume was measured for the central zone, peripheral zone, and total prostate. The outcome was analyzed using linear regression. RESULTS: We observed that prostate growth rates vary depending on age, the prostate zone, and 5ARI use. BMI and central/total prostate volume ratio are associated with the growth rate of the peripheral zone (p=0.027, p <0.001 respectively), but not the central zone growth rate. 5ARI use is significantly associated with the reduction in the central zone growth rate (Regression coefficient [RO]: -0.123 to -0.005; p=0.035), not the peripheral zone. In addition, patients with central/total prostate volume ratio greater than 60% had the most significant reduction in the central zone growth rate while taking 5ARI (RO: -0.151 to -0.063; p <0.001). CONCLUSIONS: The growth pattern of the prostate varies between the central and peripheral zones and is dependent on age and comorbidities. In addition, reduction of the prostate size as a result of the 5ARI treatment occurs mainly in the central zone. Central/total prostate volume ratio may function as a marker for 5ARI therapy sensitivity. Source of Funding: This study was supported by National Institutes of Health (NIH)/ National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH/R01 DK124502) © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e487-e487 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Xingbo Long More articles by this author Christina Sharkey More articles by this author Zongwei Wang More articles by this author Boris Gershman More articles by this author Leo Tsai More articles by this author Aria F. Olumi More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W3189683257 created "2021-08-16" @default.
• W3189683257 creator A5024094716 @default.
• W3189683257 creator A5038940108 @default.
• W3189683257 creator A5061339436 @default.
• W3189683257 creator A5068385918 @default.
• W3189683257 creator A5084739692 @default.
• W3189683257 creator A5089981020 @default.
• W3189683257 date "2021-09-01" @default.
• W3189683257 modified "2023-10-16" @default.
• W3189683257 title "MP28-17 PROSTATE ZONAL VOLUMES MAY PREDICT 5ARI THERAPY RESPONSIVENESS" @default.
• W3189683257 doi "https://doi.org/10.1097/ju.0000000000002025.17" @default.
• W3189683257 hasPublicationYear "2021" @default.
• W3189683257 type Work @default.
• W3189683257 sameAs 3189683257 @default.
• W3189683257 citedByCount "0" @default.
• W3189683257 crossrefType "journal-article" @default.
• W3189683257 hasAuthorship W3189683257A5024094716 @default.
• W3189683257 hasAuthorship W3189683257A5038940108 @default.
• W3189683257 hasAuthorship W3189683257A5061339436 @default.
• W3189683257 hasAuthorship W3189683257A5068385918 @default.
• W3189683257 hasAuthorship W3189683257A5084739692 @default.
• W3189683257 hasAuthorship W3189683257A5089981020 @default.
• W3189683257 hasBestOaLocation W31896832571 @default.
• W3189683257 hasConcept C121608353 @default.
• W3189683257 hasConcept C126322002 @default.
• W3189683257 hasConcept C126894567 @default.
• W3189683257 hasConcept C2775874879 @default.
• W3189683257 hasConcept C2776235491 @default.
• W3189683257 hasConcept C2777562237 @default.
• W3189683257 hasConcept C2778878792 @default.
• W3189683257 hasConcept C2779478474 @default.
• W3189683257 hasConcept C2780192828 @default.
• W3189683257 hasConcept C2910366748 @default.
• W3189683257 hasConcept C29456083 @default.
• W3189683257 hasConcept C71924100 @default.
• W3189683257 hasConceptScore W3189683257C121608353 @default.
• W3189683257 hasConceptScore W3189683257C126322002 @default.
• W3189683257 hasConceptScore W3189683257C126894567 @default.
• W3189683257 hasConceptScore W3189683257C2775874879 @default.
• W3189683257 hasConceptScore W3189683257C2776235491 @default.
• W3189683257 hasConceptScore W3189683257C2777562237 @default.
• W3189683257 hasConceptScore W3189683257C2778878792 @default.
• W3189683257 hasConceptScore W3189683257C2779478474 @default.
• W3189683257 hasConceptScore W3189683257C2780192828 @default.
• W3189683257 hasConceptScore W3189683257C2910366748 @default.
• W3189683257 hasConceptScore W3189683257C29456083 @default.
• W3189683257 hasConceptScore W3189683257C71924100 @default.
• W3189683257 hasIssue "Supplement 3" @default.
• W3189683257 hasLocation W31896832571 @default.
• W3189683257 hasOpenAccess W3189683257 @default.
• W3189683257 hasPrimaryLocation W31896832571 @default.
• W3189683257 hasRelatedWork W1964928662 @default.
• W3189683257 hasRelatedWork W1991145424 @default.
• W3189683257 hasRelatedWork W2032816548 @default.
• W3189683257 hasRelatedWork W2223219573 @default.
• W3189683257 hasRelatedWork W2768915954 @default.
• W3189683257 hasRelatedWork W2790785354 @default.
• W3189683257 hasRelatedWork W3174598318 @default.
• W3189683257 hasRelatedWork W4229374532 @default.
• W3189683257 hasRelatedWork W4313232132 @default.
• W3189683257 hasRelatedWork W2474513771 @default.
• W3189683257 hasVolume "206" @default.
• W3189683257 isParatext "false" @default.
• W3189683257 isRetracted "false" @default.
• W3189683257 magId "3189683257" @default.
• W3189683257 workType "article" @default.